Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dermata Therapeutics ( (DRMA) ) has issued an update.
On February 23, 2026, Dermata Therapeutics, Inc. announced that board member Mary Fisher has submitted her resignation from the company’s Board of Directors, effective March 31, 2026. The company stated that her departure was not due to any disagreement over Dermata’s operations, policies or practices, but was instead prompted by restrictions imposed after her employer was recently acquired.
Following Fisher’s exit, Dermata’s Board will be reduced in size from eight directors to seven, signaling a minor change in the company’s governance structure. The orderly nature of the transition suggests limited disruption to Dermata’s strategic direction, though investors and other stakeholders may monitor how the reduced board composition influences oversight and decision-making going forward.
The most recent analyst rating on (DRMA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Dermata Therapeutics stock, see the DRMA Stock Forecast page.
Spark’s Take on DRMA Stock
According to Spark, TipRanks’ AI Analyst, DRMA is a Neutral.
The score is primarily held back by pre-revenue financial performance, persistent losses, and heavy cash burn that imply ongoing financing/dilution risk. Technicals are mixed (short-term improvement but weak longer-term trend), while valuation metrics are not supportive due to negative earnings and no indicated dividend yield. Corporate events provide some funding relief but introduce uncertainty from a major strategic pivot.
To see Spark’s full report on DRMA stock, click here.
More about Dermata Therapeutics
Dermata Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing dermatology treatments. The company operates in the healthcare and life sciences sector, targeting skin conditions through innovative therapeutic approaches for patients and providers in dermatology markets.
Average Trading Volume: 2,180,077
Technical Sentiment Signal: Sell
Current Market Cap: $4.29M
Find detailed analytics on DRMA stock on TipRanks’ Stock Analysis page.